Multiple Therapies in Treating Patients With Advanced Neuroblastoma
NCT00040872
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapie... Read More
Gender:
ALL
Ages:
50 years and below
Trial Updated:
03/06/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Neuroblastoma
Register for Updates
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00072319
Completed
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, and paclitaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery. Giving chemotherapy drugs after surgery may kill any remaining tumor cells. PURPOSE: Pilot trial to study the effectiveness of neoadjuvant or adjuvant epirubicin, cyclophosphamide, and paclitaxel in treating women who ha... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/01/2013
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Breast Cancer
Register for Updates
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
NCT00429182
Completed
The goal of this clinical research study is to learn the relationship of high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast cancer. The study also will investigate the role of CTCs in breast cancer.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2013
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
Register for Updates
Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
NCT00002649
Completed
Randomized phase III trial to compare the effectiveness of interleukin-2 with that of observation following radiation therapy, combination chemotherapy, and peripheral stem cell transplantation in treating patients who have refractory or relapsed non-Hodgkin's lymphoma. Interleukin-2 may stimulate a person's white blood cells to kill non-Hodgkin's lymphoma cells. Giving interleukin-2 after radiation therapy, chemotherapy, and peripheral stem cell transplantation may kill more cancer cells
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
02/27/2013
Locations: Southwest Oncology Group, San Antonio, Texas
Conditions: Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Register for Updates
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
NCT00003204
Completed
Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy followed by rituximab or observation in treating patients who have stage III or stage IV low-grade non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2013
Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts
Conditions: Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Small Lymphocytic Lymphoma
Register for Updates
Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
NCT00429026
Terminated
Primary Objectives: 1. To compare the overall survival of metastatic renal cell carcinoma (RCC) patients undergoing HLA-matched related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) using fludarabine-melphalan (FM) versus fludarabine-cyclophosphamide (FC) conditioning regimen. 2. To assess both cytotoxic T lymphocyte reactivity and antibodies activity against potential tumor antigenic peptides involved in graft-versus-RCC effect. Secondary Objectives: 1. To s... Read More
Gender:
ALL
Ages:
65 years and below
Trial Updated:
02/26/2013
Locations: U.T. M.D. Anderson Cancer Center, Houston, Texas
Conditions: Renal Cell Cancer
Register for Updates
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
NCT00136539
Completed
The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/15/2013
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Breast Cancer
Register for Updates
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
NCT01074060
Completed
RATIONALE: There are different methods of stem cell mobilization, such as using colony-stimulating factors alone or following chemotherapy priming. More recently, the combination of plerixafor and colony-stimulating factors has been shown to enhance stem cell mobilization. This study will assess whether the combination of plerixafor and Granulocyte Colony-Stimulating Factor (G-CSF) is effective following chemotherapy mobilization with cyclophosphamide. PURPOSE: To assess the safety, tolerabilit... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/13/2013
Locations: City of Hope, Duarte, California
Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Register for Updates
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer
NCT00003136
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of amifostine, carboplatin and cyclophosphamide, followed by peripheral stem cell transplantation, in treating patients with epithelial ovarian cancer or primary peritone... Read More
Gender:
FEMALE
Ages:
65 years and below
Trial Updated:
02/08/2013
Locations: University of Chicago Cancer Research Center, Chicago, Illinois
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
NCT00003595
Completed
Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without monoclonal antibody therapy in treating patients who have previously untreated HIV-associated non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not ye... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2013
Locations: USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California +12 locations
Conditions: Lymphoma
Register for Updates
Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors
NCT00003288
Completed
Phase I trial to study the effectiveness of tirapazamine plus cyclophosphamide in treating children who have refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/04/2013
Locations: University of Alabama Comprehensive Cancer Center, Birmingham, Alabama +27 locations
Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Register for Updates
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
NCT00007982
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well chemotherapy and peripheral stem cell transplant work in treating patients with central nervous system cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2013
Locations: Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York
Conditions: Brain and Central Nervous System Tumors, Head and Neck Cancer, Lymphoma
Register for Updates